AR065404A1 - Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero - Google Patents

Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero

Info

Publication number
AR065404A1
AR065404A1 ARP080100692A ARP080100692A AR065404A1 AR 065404 A1 AR065404 A1 AR 065404A1 AR P080100692 A ARP080100692 A AR P080100692A AR P080100692 A ARP080100692 A AR P080100692A AR 065404 A1 AR065404 A1 AR 065404A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
heteroalkyl
heterocycloalkyl
alkyl
Prior art date
Application number
ARP080100692A
Other languages
English (en)
Inventor
Vincent Guerlavais
Nils Lonberg
Qian Zhang
Liang Chen
Sanjeev Gangwar
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of AR065404A1 publication Critical patent/AR065404A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgacion provee conjugados fármaco-ligando que son potentes citotoxinas e incluyen un enlazante entre el fármaco y el ligando, en los cuales el enlazante es un unico aminoácido. La divulgacion también está dirigida a composiciones quecontienen los conjugados fármaco-ligando, y a métodos de tratamiento que los emplean. Reivindicacion 1: Un compuesto de la formula (1) en el cual L1 es un grupo alquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilosustituido o no sustituido o heteroalquilo sustituido o no sustituido; m es un entero 0, 1, 2, 3, 4, 5, o 6; AA1 es un aminoácido seleccionado desde el grupo que consiste en aminoácidos naturales y alfa-aminoácidos no naturales; L2 es alquilosustituido, alquilo no sustituido, heteroalquilo sustituido, heteroalquilo no sustituido, heterocicloalquilo no sustituido, heterocicloalquilo sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido; L3 es alquilosustituido o no sustituido, heteroalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, o heterocicloalquilo sustituido o no sustituido; o es 0 o 1; L4 es un miembro enlazante; p es 0 o 1; X4es un miembro seleccionado desde el grupo que consiste en grupos funcionales reactivos protegidos, grupos funcionales reactivos no protegidos, marcadores detectables, y agentes de direccion; y D comprende une estructura (2) en la cual es sistemaanular A es arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido o heterocicloalquilo sustituido o no sustituido; E y G son miembros seleccionados de manera independiente de entre H, alquilo sustituido o no sustituido,heteroalquilo sustituido o no sustituido, un heteroátomo, y un enlace simple, o E y G están unidos entre si para formar un sistema anular seleccionado de entre arilo sustituido y no sustituido, heteroarilo sustituido y no sustituido yheterocicloalquilo sustituido y no sustituido; X es un miembro seleccionado de entre O, S y NR23; R23 es H, alquilo sustituido o no sustituido, heteroalquilo sustituido o no sustituido o acilo; R3 es OR11, en donde R11 es H, alquilo sustituido,alquilo no sustituido, heteroalquilo sustituido, heteroalquilo no sustituido, difosfato, trifosfato, acilo, C(O)R12R13, , C(O)OR12. C(O)NR12R13, P(O)(OR12)2, C(O)CHR12R13, SR12, o SiR12R13R14, en donde R12, R13 y R14 son miembros seleccionados demanera independiente de entre H, alquilo sustituido o no sustituido, heteroalquilo sustituido y no sustituido y arilo sustituido y no sustituido, en donde R12 y R13 en conjunto con el átomo de nitrogeno o de carbono al cual están unidos estánopcionalmente unidos entre sí para formar un sistema anular heteroalquilo sustituido o no sustituido que tiene de 4 a 6 miembros, que opcionalmente contiene dos o más heteroátomos; R4, R4', R5 y R5' son miembros seleccionados de manera independientedesde el grupo que consiste en H, alquilo sustituido, alquilo no sustituido, arilo sustituido, arilo no sustituido, heteroarilo sustituido, heteroarilo no sustituido, heterocicloalquilo sustituido, heterocicloalquilo no sustituido, halogeno NO2,SO3, SO2R15, NR15R16, NR16C(O)R15, OC(O)NR15R16, OC(O)OR15, C(O)R15, SR15, OR15, CR15=NR16 y O(CH2)nN(CH3)2, o cualquier par adyacente de R4, R4'm R5 y R5'm, en conjunto con los átomos de carbono a los cuales ellos están unidos, están unidos entresí para formar un sistema anular cicloalquilo sustituido o no sustituido o heterocicloalquilo que tiene de 4 a 6 miembros; en el cual n es un entero desde 1 hasta 20; R15 y R16 son seleccionados de manera independiente de entre H, alquilo sustituidoo no sustituido, heteroalquilo sustituido o no sustituido, arilo, sustituido o no sustituido, heteroarilo sustituido y no sustituido, heterocicloalquilo sustituido y no sustituido, y peptidilo sustituido y no sustituido, ene. cual R15 y R16 enconjunto con el átomo de nitrogeno al cual están unidos están opcionalmente unidos entre si para formar un sistema anular heterocicloalquilo sustituido o no sustituido que tiene de 4 a 6 miembros, que opcionalmente contiene dos o más heteroátomos;R6 es un enlace simple que ya sea está presente o ausente y cuando está presente R6 y R7 están unidos entre sí para formar un anillo ciclopropilo; y R7 es CH2-X1 o -CH2- unido en dicho anillo ciclopropilo con R6, en el cual X1 es un grupo saliente,en el cual al menos uno de entre R4, R4', R5 y R5', R11, R12, R13, R15 o R16 enlaza D con el resto del compuesto; o una sal farmacéuticamente aceptable del mismo.
ARP080100692A 2007-02-21 2008-02-20 Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero AR065404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89102807P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
AR065404A1 true AR065404A1 (es) 2009-06-03

Family

ID=39636949

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100692A AR065404A1 (es) 2007-02-21 2008-02-20 Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero

Country Status (12)

Country Link
US (1) US8664407B2 (es)
EP (1) EP2121667B1 (es)
JP (1) JP2010519310A (es)
KR (1) KR20090122439A (es)
CN (1) CN101616911A (es)
AR (1) AR065404A1 (es)
AU (1) AU2008218766A1 (es)
CA (1) CA2678514A1 (es)
CL (1) CL2008000510A1 (es)
IL (1) IL200113A0 (es)
TW (1) TW200900059A (es)
WO (1) WO2008103693A2 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412367B (zh) * 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CN101951946B (zh) 2007-10-01 2014-12-10 百时美施贵宝公司 结合间皮素的人抗体及其应用
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20130030359A1 (en) * 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089903A1 (en) 2010-01-25 2011-07-28 Panasonic Corporation A method for immobilizing protein a on a self-assembled monolayer
KR101901555B1 (ko) 2010-04-21 2018-09-21 신타가 비.브이. Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
US10227289B2 (en) 2010-05-07 2019-03-12 Medicus Biosciences, Llc Methods for treating diseases of the lung
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2012029202A1 (en) * 2010-08-30 2012-03-08 Panasonic Corporation A method for immobilizing streptavidin on a self-assembled monolayer
WO2012053138A1 (ja) 2010-10-19 2012-04-26 パナソニック株式会社 グルコースオキシダーゼを自己組織化膜上に固定する方法
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) * 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
AU2013221873B2 (en) 2012-02-13 2016-11-17 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
JP6206987B2 (ja) 2012-05-11 2017-10-04 メディカス バイオサイエンシーズ，エルエルシー 網膜剥離の処置のための生体適合性ヒドロゲル製剤
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2956173B1 (en) 2013-02-14 2017-03-29 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
ES2741207T3 (es) 2013-03-15 2020-02-10 Zymeworks Inc Compuestos citotóxicos y antimitóticos, y métodos de uso de los mismos
US9975942B2 (en) 2013-11-11 2018-05-22 Wake Forest University Health Services EPHA3 And multi-valent targeting of tumors
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
HUE029672T2 (en) 2014-01-10 2017-03-28 Synthon Biopharmaceuticals Bv Duokarmicin-ADCs for use in the treatment of endometrial cancer
SG11201605605SA (en) 2014-01-10 2016-08-30 Synthon Biopharmaceuticals Bv Method for purifying cys-linked antibody-drug conjugates
JP6342517B2 (ja) 2014-01-10 2018-06-13 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 改善されたインビボ抗腫瘍活性を示すデュオカルマイシンａｄｃ
IL309933A (en) 2014-02-17 2024-03-01 Seagen Inc Hydrophilic antibody-drug conjugates
ES2898273T3 (es) 2014-03-20 2022-03-04 Bristol Myers Squibb Co Moléculas con una estructura a base de fibronectina estabilizada
JP6787789B2 (ja) * 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
KR102204937B1 (ko) 2014-06-06 2021-01-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016041082A1 (en) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
HUE052526T2 (hu) 2014-11-21 2021-05-28 Bristol Myers Squibb Co Antitestek, amelyek tartalmaznak módosított nehéz konstans régiókat
CN107406494B (zh) 2014-11-25 2022-03-25 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
EP3223866B1 (en) 2014-11-25 2023-03-08 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
JP2018508463A (ja) * 2014-12-09 2018-03-29 アッヴィ・インコーポレイテッド 低細胞透過性を有するＢｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
AU2015360621A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Bcl-xL inhibitory compounds and antibody drug conjugates including the same
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
SG11201705645YA (en) 2015-01-14 2017-08-30 Bristol Myers Squibb Co Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
EP3353198B1 (en) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017176648A1 (en) * 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
US10287291B2 (en) 2016-08-19 2019-05-14 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018208868A1 (en) 2017-05-10 2018-11-15 Smet Pharmaceutical Inc Human monoclonal antibodies against lag3 and uses thereof
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US20200363425A1 (en) * 2017-11-22 2020-11-19 Seattle Genetics, Inc. Acid-mediated assay for analyzing ligand-drug conjugates
CN111886255A (zh) 2018-01-12 2020-11-03 百时美施贵宝公司 抗tim3抗体及其用途
JP2021513990A (ja) 2018-02-20 2021-06-03 シージェン インコーポレイテッド 疎水性アウリスタチンｆ化合物およびそのコンジュゲート
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020117627A1 (en) 2018-12-03 2020-06-11 Bristol-Myers Squibb Company Anti-ido antibody and uses thereof
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
CN114144435B (zh) 2019-07-15 2024-06-25 百时美施贵宝公司 针对人trem-1的抗体及其用途
CN114174536A (zh) 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
CN110845480B (zh) * 2019-11-22 2022-03-15 荣昌生物制药(烟台)股份有限公司 一种双功能细胞毒素及其用途
WO2021146191A1 (en) 2020-01-13 2021-07-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
KR20220147642A (ko) 2020-02-27 2022-11-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Il4r에 결합하는 항체 및 이의 용도
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4417626A1 (en) 2021-10-14 2024-08-21 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
CN114181216A (zh) * 2021-12-27 2022-03-15 苏州新药篮生物医药科技有限公司 一种3,6-二氢吡咯并[3,2-e]吲哚-2-甲酸甲酯的制备方法
AR128330A1 (es) * 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4912227A (en) 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en) 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
CA1238907A (en) 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0684377B1 (es) 1986-04-17 1994-10-26 Kyowa Hakko Kogyo Kk
US5332837A (en) 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
DE3750612T2 (de) 1986-12-19 1995-03-02 Upjohn Co Cc-1065 analoge.
US5773435A (en) 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US4994578A (en) 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
US5147786A (en) 1988-04-22 1992-09-15 Monsanto Company Immunoassay for the detection of α-haloacetamides
JP2642165B2 (ja) 1988-07-22 1997-08-20 協和醗酵工業株式会社 新規ｄｃ−８９化合物およびその製造法
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5495009A (en) 1989-10-24 1996-02-27 Gilead Sciences, Inc. Oligonucleotide analogs containing thioformacetal linkages
US5334528A (en) 1989-10-30 1994-08-02 The Regents Of The University Of California Monoclonal antibodies to cyclodiene insecticides and method for detecting the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991016324A1 (en) 1990-04-25 1991-10-31 The Upjohn Company Novel cc-1065 analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69121334T2 (de) 1990-07-26 1997-03-20 Kyowa Hakko Kogyo Kk DC-89-Derivate als Antitumor-Wirkstoffe
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
JP2502005B2 (ja) 1992-04-27 1996-05-29 オンキヨー株式会社 バイオフィ―ドバックシステム
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JP3514490B2 (ja) 1992-08-21 2004-03-31 杏林製薬株式会社 トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
DE4314091A1 (de) 1993-04-29 1994-11-03 Boehringer Mannheim Gmbh Immunologisches Nachweisverfahren für Triazine
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773011A (en) 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5786377A (en) 1993-11-19 1998-07-28 Universidad De Santiago De Compostela Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications
EP0705833B1 (en) 1994-04-22 2004-07-21 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivative
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
DK0769967T3 (da) 1994-08-19 2008-03-31 Wallone Region Konjugater der omfatter et antitumormiddel, og anvendelse heraf
CA2201097A1 (en) 1994-09-30 1996-04-11 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agents
WO1996016965A1 (fr) 1994-11-29 1996-06-06 Kyorin Pharmaceutical Co., Ltd. Derives d'acrylamide et leur procede de production
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
US5686237A (en) 1995-06-05 1997-11-11 Al-Bayati; Mohammed A. S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
CA2233936A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
EP0774464B1 (en) 1995-10-17 2004-07-28 Combichem, Inc. A template for solution phase synthesis of combinatorial libraries
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US6143901A (en) 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
JP2000506168A (ja) 1996-03-08 2000-05-23 ザ スクリップス リサーチ インスティテュート Ｃｃ―１０６５及びデュオカマイシンのｍｃｂｉ類似体
US6060608A (en) 1996-05-31 2000-05-09 The Scripps Research Institute Analogs of CC-1065 and the duocarmycins
WO1998009966A1 (fr) 1996-09-03 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Derives dc-89
NZ334344A (en) 1996-09-12 2000-08-25 Cancer Res Campaign Tech benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JPH1087666A (ja) 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1998025900A1 (fr) * 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Composes presentant une activite antitumorale
CA2285259A1 (en) 1997-03-28 1998-10-08 The Scripps Research Institute Sandramycin analogs
US6132722A (en) 1997-05-07 2000-10-17 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
WO1998052925A1 (en) 1997-05-22 1998-11-26 The Scripps Research Institute Analogs of duocarmycin and cc-1065
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
US6310209B1 (en) 1997-12-08 2001-10-30 The Scripps Research Institute Synthesis of CC-1065/duocarmycin analogs
JP3045706B1 (ja) 1998-09-14 2000-05-29 科学技術振興事業団 Ｄｎａの特定塩基配列をアルキル化する化合物及びその合成法
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1144011B1 (en) 1998-12-11 2010-03-10 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
JP2003529609A (ja) 2000-03-16 2003-10-07 ジーンソフト インコーポレイティッド 核酸結合部分を含む荷電した化合物およびその利用法
WO2001083482A1 (en) 2000-05-03 2001-11-08 The Scripps Research Institute Dna alkylating agent and activation thereof
JP4061819B2 (ja) 2000-05-12 2008-03-19 独立行政法人科学技術振興機構 インターストランドクロスリンク剤の合成方法
EP1294403A2 (en) 2000-06-14 2003-03-26 Corixa Corporation Tripeptide prodrug compounds
US7115573B2 (en) 2000-06-14 2006-10-03 Medarex, Inc. Prodrug compounds with an isoleucine
WO2002015700A1 (en) 2000-08-24 2002-02-28 Coulter Pharmaceutical, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6762179B2 (en) 2001-05-31 2004-07-13 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
JP4541693B2 (ja) 2001-06-11 2010-09-08 メダレックス，インコーポレイティド Ｃｄ１０活性化プロドラッグ化合物
JP2005502703A (ja) 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
TWI492750B (zh) * 2003-01-27 2015-07-21 安德賽特公司 維生素-受體結合性藥物輸送共軛物、醫藥組合物、用途及製備方法
US20050026987A1 (en) 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
MXPA06013413A (es) * 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
JP5149620B2 (ja) * 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US20080279868A1 (en) * 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物

Also Published As

Publication number Publication date
AU2008218766A1 (en) 2008-08-28
WO2008103693A2 (en) 2008-08-28
CL2008000510A1 (es) 2008-08-22
EP2121667B1 (en) 2016-06-08
WO2008103693A3 (en) 2008-12-11
CA2678514A1 (en) 2008-08-28
JP2010519310A (ja) 2010-06-03
IL200113A0 (en) 2010-04-15
CN101616911A (zh) 2009-12-30
US8664407B2 (en) 2014-03-04
TW200900059A (en) 2009-01-01
KR20090122439A (ko) 2009-11-30
US20100113476A1 (en) 2010-05-06
EP2121667A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AR065404A1 (es) Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
AR067837A1 (es) Conjugados de farmaco-ligando y sustratos farmaco-escindibles, composiciones que los contienen; utiles en el tratamiento de tumores y cancer
IL263973A (en) Protein-polymer-drug couplings
IL275830A (en) Polyethylene glycol modified drug-linker for improved ligand-drug conjugate pharmacokinetics
JP2014528466A5 (es)
DK0909184T3 (da) Målrettet lægemiddelindgivelse ved anvendelse af sulfonamidderivater
CA2653941A1 (en) Substituted amino purine derivatives and uses thereof
CA2448319A1 (en) Cytotoxins, prodrugs, linkers and stabilizers useful therefor
BR0317928A (pt) Derivados de 1-propanol e 1-propilamina e seu uso como ligantes de glicorticóide
DE602004032553D1 (de) Polyacetal-arzneimittelkonjugate als freisetzungssystem
JP2017518304A5 (es)
BRPI0619255A8 (pt) Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
EA200001217A1 (ru) Лекарственный комплекс
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
AR035333A1 (es) Glucopeptido sustituido, composicion farmaceutica que lo comprende, su uso en la fabricacion de medicamentos utiles para tratar enfermedades bacterianas y metodo para preparar dichos compuestos.
AR096461A1 (es) Anticuerpos conjugados de fármacos
RU2015119561A (ru) Новые конъюгаты лекарственное вещество-белок
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
MY139941A (en) Indole derivatives
BR0211227A (pt) Composto, composição farmacêutica e seus usos
CO5690592A2 (es) 5-arilpirimidinas como agentes anticancer
JP2020531471A5 (es)
AR035230A1 (es) Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure